Already a Bloomberg.com user?
Sign in with the same account.
Dec. 8 (Bloomberg) -- Affymax Inc. rose 39 percent in early trading after winning a U.S. advisory panel’s backing for an experimental anemia medicine.
The shares gained $2.26 to $8.12 at 7:25 a.m. The medicine would be Palo Alto, California-based Affymax’s first product if it gains regulatory approval.
To contact the reporter on this story: Bruce Rule in London at firstname.lastname@example.org
To contact the editor responsible for this story: Bruce Rule at email@example.com